CorNeat EverPatch Hits the US Market: Farewell to Traditional Ocular Tissue Grafts
RA'ANANA, Israel, Feb. 27, 2024 /PRNewswire/ -- CorNeat Vision, a leader in innovative medical device solutions, proudly introduces the CorNeat EverPatch, a pioneering synthetic tissue-integrating matrix designed to revolutionize ophthalmic surgeries. Endorsed by leading surgeons across the US, this FDA-cleared device represents a significant leap forward in addressing complications related to surgical interventions of the ocular surface.
- The CorNeat EverPatch is a synthetic tissue substitute for ocular surface surgeries, offering a unique combination of features that provide a significant advantage over existing tissue grafts, which degrade over time.
- The CorNeat EverPatch is poised to provide an optimal solution for reinforcing tissue over glaucoma drainage devices, addressing complications such as tube exposure that often require reoperation.
- Dr. Gilad Litvin, Co-Founder and Chief Medical Officer at CorNeat Vision, emphasizes the safety and efficacy of the CorNeat EverPatch, stating, "Our synthetic tissue substitute is tear-resistant, non-degradable, and completely bio-compatible, with no observed chronic inflammatory response that exists around tissue grafts.
- We are confident that the CorNeat EverPatch will set a new standard of care in ocular surgeries necessitating scleral reinforcement."